Summaries for Patients |

Preventing Bone Loss in Men with Prostate Cancer FREE

[+] Article, Author, and Disclosure Information

The summary below is from the full report titled “Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. A Randomized Trial.” It is in the 20 March 2007 issue of Annals of Internal Medicine (volume 146, pages 416-424). The authors are S.L. Greenspan, J.B. Nelson, D.L. Trump, and N.M. Resnick.

Ann Intern Med. 2007;146(6):I-72. doi:10.7326/0003-4819-146-6-200703200-00001
Text Size: A A A

What is the problem and what is known about it so far?

Prostate cancer is often treated with surgery or drugs to lower levels of testosterone and similar hormones called androgens. These hormones stimulate cancer cells to grow, so lowering their levels usually slows or stops the growth of cancer. However, these hormones also maintain the density and strength of men's bones, so lowering their levels also leads to weaker bones and more fractures. Drugs used to treat osteoporosis prevent weak bones and fractures, and therefore, they might be useful in preventing weak bones and fractures in men with prostate cancer who receive hormone-lowering treatment.

Why did the researchers do this particular study?

To see whether alendronate, a drug used to treat osteoporosis, slows the weakening of bones in men with prostate cancer who receive hormone-lowering treatment.

Who was studied?

112 men with prostate cancer who underwent surgery or were given drugs to lower their hormone levels.

How was the study done?

The researchers measured the bone density of the men at the beginning of the study. They then randomly assigned each to receive alendronate or placebo once weekly for 1 year. After a year, they measured the men's bone density and compared changes between the 2 groups. They also measured and compared blood markers of bone stability in the 2 groups.

What did the researchers find?

Bone density increased in men who received alendronate. It decreased in men who received placebo. Blood tests showed that bones became more stable in men who received alendronate compared with those who received placebo.

What were the limitations of the study?

It was not designed to show whether alendronate reduces fractures.

What are the implications of the study?

Alendronate stabilized and strengthened the bones of men with prostate cancer who were receiving hormone-lowering treatment. Men with prostate cancer taking hormone-lowering treatments should probably have their bone density measured. They can use the information to decide with their doctors whether they should take a drug used to treat osteoporosis to prevent bone loss.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.